Related Experiment Videos
[Primary subcutaneous mantle cell lymphoma treated successfully with THP-COP therapy]
Junichi Hisatake1, Keiichiro Kawakami, Tsuyoshi Nakamaki
1Department of Hematology, Showa University School of Medicine.
Summary
A rare case of primary subcutaneous mantle cell lymphoma (MCL) in a 73-year-old man showed a complete response to chemotherapy. This aggressive non-Hodgkin lymphoma subtype, typically difficult to treat, achieved sustained remission, offering hope for similar rare presentations.
Area of Science:
- Oncology
- Hematology
- Dermatology
Background:
- Primary subcutaneous non-Hodgkin lymphoma is rare.
- Mantle cell lymphoma (MCL) is an aggressive B-cell neoplasm with a generally poor prognosis.
Observation:
- A 73-year-old man presented with multiple subcutaneous tumors on the face, chest, and arms.
- Biopsy revealed non-Hodgkin lymphoma with specific immunophenotypic markers (CD19+, CD20+, CD5+, cyclin D1+) and a t(11;14) karyotype.
- Genetic analysis did not detect bcl-1 gene rearrangement.
Findings:
- The patient was diagnosed with primary subcutaneous mantle cell lymphoma (MCL).
- Treatment with eight courses of THP-COP chemotherapy resulted in complete remission.
- Remission has been maintained for 17 months post-diagnosis.
Implications:
- This case highlights that primary subcutaneous MCL, though rare and aggressive, can be effectively treated with chemotherapy.
- The favorable response suggests potential therapeutic avenues for similar rare lymphoma presentations.
- Long-term follow-up is crucial for assessing sustained remission in primary subcutaneous MCL.